The trial evaluates the adjunctive use of Mangosteen with established diabetes medications (Sitagliptin and Metformin) in a specific population (Iraqi patients with newly diagnosed T2DM). If successful, this could position Mangosteen as a complementary therapy in the diabetes market, which is experiencing significant growth due to rising prevalence rates. The competitive landscape includes other adjunct therapies and natural supplements, necessitating a thorough market analysis and potential partnerships for commercialization. Diligence should focus on the safety profile and efficacy data to assess market entry viability.